Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Sells $494,872.00 in Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $494,872.00. Following the transaction, the chief financial officer now owns 633,515 shares in the company, valued at approximately $5,068,120. This trade represents a 8.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Aurinia Pharmaceuticals Trading Up 7.3 %

Shares of AUPH opened at $8.67 on Thursday. The firm has a market cap of $1.24 billion, a P/E ratio of -57.80 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The company has a 50 day simple moving average of $8.13 and a two-hundred day simple moving average of $7.86.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently bought and sold shares of AUPH. SBI Securities Co. Ltd. purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $27,000. Tower Research Capital LLC TRC increased its holdings in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $31,000. Finally, Natixis bought a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $49,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.